INCRAFT™ AAA Stent-Graft System One-Year Follow-Up Data Presented at 2012 Veith Symposium

  INCRAFT™ AAA Stent-Graft System One-Year Follow-Up Data Presented at 2012
  Veith Symposium

   Study Demonstrates Safety and Efficacy of New Customizable and Ultra-Low
  Profile Stent-Graft System for the Treatment of Abdominal Aortic Aneurysms

Business Wire

BRIDGEWATER, N.J. -- November 19, 2012

Cordis Corporation today announced the presentation of the INCRAFT™ AAA
Stent-Graft System INNOVATION study one-year results at the 2012 Veith
Symposium in New York City.

Investigator Professor Gioachino Coppi, MD, from the University of Modena and
Reggio Emilia in Italy, presented the results of the INNOVATION study (A
MULTICENTER, OPEN LABEL, PROSPECTIVE, NON-RANDOMIZED STUDY OF INCRAFT™ IN
SUBJECTS WITH ABDOMINAL AORTIC ANEURYSMS) on behalf of the study
investigators.

The INNOVATION study assesses the safety and efficacy of the INCRAFT™ System
in treating patients with abdominal aortic aneurysms (AAA) at investigational
sites in Germany and Italy. An estimated 24 million people worldwide have
abdominal aortic aneurysms. Left untreated, most aneurysms will eventually
rupture, with life-threatening consequences. In the U.S. alone, approximately
15,000 people die every year due to an AAA rupture.

“The INNOVATION trial results to date demonstrate favorable one year clinical
outcome of the INCRAFT™ System with AAA. The innovative technologies of the
INCRAFT™ System make it a valuable option to treat AAA patients in the future,
including those that are currently not considered eligible for endovascular
treatment,” said the study’s principal investigator, Professor Dierk
Scheinert, head of the Department of Medicine, Angiology and Cardiology at
Park-Krankenhaus Hospital in Leipzig.

The INNOVATION clinical study results at one-year follow-up demonstrate strong
performance by the INCRAFT™ System. At one-year follow-up there were zero
incidences of aneurysm enlargement, endoleaks (type I, III or IV), device or
procedure related major adverse events, stent-graft migrations or stent
fractures. All stent-grafts remained patent at one-year follow-up.

“We are excited about the clinical results for this innovative new
endovascular AAA technology,” said Shlomi Nachman, Worldwide President, Cordis
Corporation. “The INCRAFT™ System is designed to overcome the limitations of
current AAA stent-grafts with its ultra-low profile, proximal and distal
placement accuracy, ability to be customized during the procedure and broad
anatomical coverage with a minimal number of product codes. We believe the
INCRAFT™ System has the potential to set a new standard in the field of
endovascular AAA.”

Most traditional EVAR stent grafts available in the US and Japan have a system
profile ranging from 18 to 24 French. The INCRAFT™ System provides an
integrated delivery system with a profile equivalent to that of a regular 13
French catheter sheath introducer.

Cordis developed INCRAFT™, which is currently being investigated in a US-Japan
pivotal clinical study, INSPIRATION, with input from a multidisciplinary
Physician Advisory Panel that includes Dr. Corey Teigen, Department of
Interventional Radiology, Sanford Medical Center, Fargo, ND, Dr. Takao Ohki,
M.D., Chairman of the Department of Surgery at Jikei University School of
Medicine in Tokyo, and Dr. Robert Bersin, M.D., Medical Director, Endovascular
Services, Swedish Medical Center, Seattle, WA. The INSPIRATION pivotal study
is being led by principal investigators Dr. Ohki and Dr. Michel S. Makaroun,
M.D., Professor and Chair of the Division of Vascular Surgery at the
University Of Pittsburgh School Of Medicine.

The INCRAFT™ System is approved for investigational device use only and it not
for sale anywhere in the world.

Drs. Bersin, Makaroun, Ohki, Scheinert and Teigen are compensated for their
consulting services and/or as members of the company’s scientific advisory
board.

About Cordis Corporation

Cordis Corporation, part of the Johnson & Johnson family of companies, is a
worldwide leader in the development and manufacture of interventional vascular
technology. Through the company's innovation, research and development, Cordis
partners with interventional cardiologists worldwide to treat millions of
patients who suffer from vascular disease. More information about Cordis
Corporation can be found at www.cordis.com.

(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Johnson & Johnson.
Risks and uncertainties include, but are not limited to, general industry
conditions and competition; economic factors, such as interest rate and
currency exchange rate fluctuations; technological advances, new products and
patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approvals; challenges to patents;
significant adverse litigation or government action; impact of business
combinations; financial distress and bankruptcies experienced by significant
customers and suppliers; changes to governmental laws and regulations and
domestic and foreign health care reforms; trends toward health care cost
containment; increased scrutiny of the health care industry by government
agencies; changes in behavior and spending patterns of purchasers of health
care products and services; financial instability of international economies
and sovereign risk; disruptions due to natural disasters; manufacturing
difficulties or delays; and product efficacy or safety concerns resulting in
product recalls or regulatory action. A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of Johnson &
Johnson's Annual Report on Form 10-K for the fiscal year ended January 1,
2012. Copies of this Form 10-K, as well as subsequent filings, are available
online at www.sec.gov, www.investor.jnj.com or on request from Johnson &
Johnson. Johnson & Johnson does not undertake to update any forward-looking
statements as a result of new information or future events or developments.)

Contact:

For Cordis Corporation
Sandy Pound
(o) 908-218-2720
(m) 908-432-2829
spound@its.jnj.com
 
Press spacebar to pause and continue. Press esc to stop.